Summary
To assess the effects of ACE-inhibition on insulin action in Type 2 (non-insulin-dependent) diabetes mellitus associated with essential hypertension, 12 patients with Type 2 diabetes (on diet and oral hypoglycaemic agents) and arterial hypertension were examined on two occasions, in a single blind, cross-over study, after two days of treatment with either captopril or a placebo. The study consisted of a euglycaemic-hyperinsulinaemic clamp (two sequential steps of insulin infusion at the rates of 0.25 mU·kg−1·min−1 and 1 mU·kg−1·min−1, 2 h each step), combined with an infusion of 3-3H-glucose to measure the rate of hepatic glucose production and that of peripheral glucose utilization. The results show that blood pressure was lower after captopril (sitting, systolic 148±5 mmHg, diastolic 89±2 mm Hg) compared to placebo (155±6 and 94±2 mm Hg) (p<0.05). Captopril treatment resulted in a more suppressed hepatic glucose production (2.7±0.4 vs 4.94±0.55 μmol·kg−1·min−1), and a lower plasma non-esterified fatty acid concentration (0.143±0.05 vs 0.200±0.05 mmol/l) (captopril vs placebo, p<0.05) at the end of the first step of insulin infusion (estimated portal plasma insulin concentration 305±28 pmol/l); and in a greater glucose utilization (36.5±5.1 vs 28±3.6μmol·kg−1·min−1, p<0.001) at the end of the second step of insulin infusion (arterial plasma insulin concentration of 604±33 pmol/l). We conclude that captopril improved insulin sensitivity in Type 2 diabetes associated with hypertension at the level of the liver and extrahepatic tissues, primarily muscle and adipose tissue. Thus, in contrast to other antihypertensive drugs such as diuretics and beta-blockers which may have a detrimental effect on insulin action, ACE-inhibitors appear to improve insulin action in Type 2 diabetes and essential hypertension, at least on a short-term basis.
Article PDF
Similar content being viewed by others
References
Fuller JH (1985) Epidemiology of hypertension associated with diabetes mellitus. Hypertension 7 [Suppl 2]: 3–7
The Working Group on Hypertension in Diabetes (1987) Statement on hypertension in diabetes mellitus. Arch Intern Med 147: 830–842
The 1984 Report Of The Joint National Committee on Detection, Evaluation, and treatment of high blood pressure (1984). Arch Intern Med 144: 1405–1507
Furman BL (1981) Impairment of glucose tolerance produced by diuretics and other drugs. Pharmacol Ther 12: 613–649
Dimitriadis G, Leighton B, Parry-Billings M, Newsholme EA (1988) Effects of the diuretic furosemide on the sensitivity of glycolysis and glycogen synthesis to insulin in the soleus muscle of the rat. Diabetologia 31: 58–61
Östman J (1983) Beta-adrenergic blockade and diabetes mellitus. A review. Acta Med Scand 672 [Suppl]: 69–77
Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljunghall S (1989) Metabolic effects of diltiazem and atenolol: results from a randomized double-blind study with parallel groups. J Hypertens 7: 551–559
Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, Varricchio M (1980) Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol 18: 395–398
De Marinis L, Barbarino A (1980) Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor. Metabolism 29: 599–604
Charles S, Ketelslegers J-M, Buysschaert M, Lambert A (1981) Hyperglycaemic effects of nifedipine. Br Med J 283: 19–20
Bhatnagar SK, Amin MMA, Al-Yusuf AR (1984) Diabetogenic effects of nifedipine. Br Med J 289: 19
Donnelly T, Harrower AD (1980) Effect of nifedipine on glucose tolerance and insulin secretion in diabetic and non-diabetic patients. Curr Med Res Opin 6: 690–693
Marre M, Bellet M, Leblanc H, Passa P (1986) Dissociated effects of nicardipine on vascular tone and insulin secretion. J Cardiovasc Pharmacol 8: 707–711
Collins WCJ, Cullon MJ, Ferley J (1987) Calcium channel blocker drugs and diabetic control. Clin Pharmacol Ther 42: 420–423
Pasanisi F, Vaccaro O, Ferrara AL, Di Bonito P, Capaldo B, Iovine C, Mancini M (1989) Effect of nicardipine on insulin secretion, glucose and lipid metabolism in hypertensive, non-insulin dependent diabetes. Eur J Clin Pharmacol 36: 1–4
Belleville I, Vaillant G, Farmer M, Brun JM (1987) La nicardipine peut avoir un effet délétère sur l'équilibre glycémique du diabétique non insulinodépendant. Presse Méd 16: 1760–1761
Skarfors ET, Lithell HO, Selinus I, Aberg H (1989) Do antihypertensive drugs precipitate diabetes in predisposed man? Br Med J 298: 1147–1152
Schonfeld MR, Goldberger E (1986) Hypercholesterolemia induced by thiazides: a pilot study. Curr Ther Res 6: 180–184
Weidman P, Gerber A, Mordasini R (1983) Effects of antihypertensive therapy on serum lipoproteins. Hypertension 5 [Supl 3]: 120–131
Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin treatment with atenolol and metoprolol: a randomised double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 298: 1152–1157
Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G (1987) Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 17: 448–454
Pollare T, Lithell H, Berne C (1989) A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321: 868–873
De Fronzo R (1988) The triumvirate: B-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667–687
Ferrannini E, Buzzigoli G, Bonadonna R et al. (1987) Insulin resistance in essential hypertension. N Engl J Med 317: 350–357
Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouza J (1985) Captopril and insulin sensitivity. Ann Intern Med 102: 134–135
Lederle RM (1985) Captopril and hydrochlorothiazide in the fixed combination multicenter trial. J Cardiovasc Pharmacol 7 [Suppl]: 63–69
McMurray J, Fraser DM (1986) Captopril, enalapril, and blood glucose, Lancet I: 1305
Sawicki PT, Mühlhauser I, Baba T, Berger M (1990) Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Diabetologia 33: 121–124
Andres R, Swerdloff T, Pozefsky T, Coleman D (1966) Manual feedback technique for the control of blood glucose concentration. In: Lt Skeggs Jr (Ed) Automatism in analytical chemistry. New York, Mediad, pp 486–491
McGuire E, Helderman J, Tobin R, Andres R, Berman M (1976) Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 41: 565–573
De Feo P, Perriello G, Ventura MM et al. (1986) Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: relevance to the pathogenesis of the dawn phenomenon. Diabetologia 29: 475–480
De Feo P, Perriello G, De Cosmo S et al. (1986) Comparison of glucose counterregulation during short-term and prolonged hypoglycemia in normal humans. Diabetes 35: 563–569
Rizza A, Cryer PE, Gerich JE (1979) Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation: effects of somatostatin and combined a- and b-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest 64: 62–71
Herbert V, Lav KS, Gottlieb G, Bleicher SJ (1965) Coated charcoal immunoassay of insulin. J Endocrinol Metab 25: 1375–1379
Faber O, Binder C, Markussen J, Heding L, Naithand V, Kuzuya H, Blix P, Horwitz D, Rubenstein A (1978) Characterization of seven C-peptide antisera. Diabetes 27 [Suppl 1]: 170–177
NEFA C. Enzymatic colorimetric method for the quantitative determination of FFA in serum. Wako Chemicals, Neuss
De Bodo R, Steele R, Altzuler N, Dunn A, Bishop J (1963) On the hormonal regulation of carbohydrate metabolism: studies with C14 glucose. Recent Prog Horm Res 19: 445–448
Miles J, Haymond M, Gerich JE (1982) Effects of free fatty acids, insulin glucagon and adrenalin on ketone body production in humans. In: Metabolic acidosis, Ciba Foundation Symposium 87, Pitman, London, pp 192–213
Eaton R, Allen R, Shade D, Erickson K, Standefer J (1980) Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behaviour. J Clin Endocrin Metab 51: 520–528
Zar J (1984) Biostatistical analysis. Prentice Hall, Englewood Cliffs New Yersey
Miles JM, Rizza RA, Haymond MW, Gerich JE (1980) Effects of acute insulin deficiency on glucose and ketone body turnover in man. Diabetes 29: 926–930
Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE (1984) Defective glucose counterregulation after subcutaneous insulin in non-insulin dependent diabetes mellitus: paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest 73: 1532–1541
Rizza M, Mandarino L, Gerich J (1981) Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240: E630-E639
Nurjhan N, Campbell PJ, Kennedy FP, Miles JM, Gerich JE (1986) Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans. Diabetes 35: 1326–1331
Cobelli C, Mari A, Ferrannini E (1987) The non-steady state problem: error analysis of Steele's model and new development for glucose kinetics. Am J Physiol 252: E679-E689
Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB (1990) Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33: 52–59
Gerich JE (1988) Role of insulin resistance in the pathogenesis of NIDDM. Balliere's Clin Endocrinol Metab 2: 307–326
Trovati M, Mularoni E, Massucco P, Burzacca S, Malvaso MR, Anfossi G, Emanuelli G (1989) Study on the occurrence of blood glucose concentrations under the target of 4.4 mmol/l in a cohort of 463 Type 2 diabetic patients. Diabetologia 32: 549A
Douglas WW (1985) Polypeptides-angiotensin, plasma kinins and others. In: Goodman LS and Gilman JAG (eds) The pharmacological basis of therapeutics. MacMillan, New York, pp 639–659
Pollare T, Lithell H, Selinus I, Berne C (1988) Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 31: 415–420
Dietze GJ (1982) Modulation of the action of insulin in relation to the energy state in skeletal muscle. Possible involvement of kinins and prostaglandins. Mol Cell Endocrinol 25: 127–149
Jauch K-W, Guenther B, Hartl W, Rett K, Wicklmayr M, Dietze G (1986) Improvement of impaired postoperative insulin action by bradykinin. Biol Chem Hoppe-Seyler 367: 207–210
De Feo P, Bolli GB, Motolese M, Brunetti P (1989) Benazepril improves glycaemic control in patients with Type 2 diabetes and essential hypertension. The International Symposium on ACE-inhibition, London, February 14–17, Abs F078
Seefeldt T, Orskov L, Rasmussen O, Pedersen MM, Moller N, Christiansen JS, Schmitz O (1990) Lack of effects of angiotensinconverting enzyme inhibitors on glucose metabolism in insulindependent diabetes mellitus. Diabetic Med 7: 700–704
Unger R, Grundy S (1985) Hyperglycemia as an inducer as well as a consequence of impaired islet function and insulin resistance: implication for the management of diabetes. Diabetologia 28: 119–121
Stout RW (1985) Overview of the association between insulin and atherosclerosis. Metabolism 34 [Suppl 1]: 7–12
Wingard DL, Barrett-Connor E (1987) Family history of diabetes and cardiovascular disease risk factors and mortality among euglycemic, borderline hyperglycemic and diabetic adults. Am J Epidemiol 125: 948–958
Ferrannini E, De Fronzo R (1989) The association of hypertension, diabetes, and obesity: a review. J Nephrol 1: 3–15
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Torlone, E., Rambotti, A.M., Perriello, G. et al. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 34, 119–125 (1991). https://doi.org/10.1007/BF00500383
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF00500383